article thumbnail

Automated red blood cell exchange: bridging treatment gaps in sickle cell disease care

Drug Target Review

Dr Aaron Haubner, Senior Manager of North America Medical Affairs and Market Access at Terumo Blood and Cell Technologies , reveals that while promising new treatments emerge, urgent partnerships are needed to ensure this essential blood therapy reaches the patients who need it most.

article thumbnail

2025 Merkin Prize in Biomedical Technology awarded to pioneers of CAR T-cell therapy

Broad Institute

The work of June, Levine, Rivire, and Sadelain laid the foundation for a whole new class of treatments. In 2007, Sadelain and Rivire treated their first patient with leukemia, and in 2009, published details on how they manufactured personalized CAR T cells to treat patients with aggressive leukemia.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Gepirone

New Drug Approvals

4] It was approved for the treatment of major depressive disorder in the United States in September 2023. [4] 4] It was approved for the treatment of major depressive disorder in the United States in September 2023. [4] 4] It was approved for the treatment of major depressive disorder in the United States in September 2023. [4]

FDA
article thumbnail

Inavolisib

New Drug Approvals

1, 2007, 41-44) (2.30 8] Therefore, it may serve as a new addition to combination therapy with conventional cancer treatment, such as chemotherapy. Combining inavolisib with palbociclib and fulvestrant might improve treatment of breast cancer. [14] mmol) in methanol (5.0 Hz, 1H), 6.41 (dd, J=8.8, Hz, 1H), 6.16 (d, J=7.2

FDA
article thumbnail

BioSensics Joins KIF1A.ORG’s Mission to Support KAND Natural History Study

KIF1A

By building a richer dataset, we not only improve our understanding of the progression and variability of KAND, but also make significant strides toward being clinical trial ready when a treatment becomes available. We are honored to partner with such passionate and visionary leaders in the rare disease community.

article thumbnail

PRITELIVIR MESYLATE

New Drug Approvals

It is being investigated as a potential treatment for various herpes infections, including those resistant to traditional antivirals like acyclovir. Pritelivir (development codes AIC316 or BAY 57-1293 ) is a direct-acting antiviral drug in development for the treatment of herpes simplex virus infections (HSV).

article thumbnail

Syringe services for people who inject drugs are enormously effective, but remain underused

National Institute on Drug Abuse: Nora's Blog

Contrary to worries that syringe services programs (SSPs) will encourage or promote drug use, evidence shows that they more often do the opposite, linking people with addiction to effective treatment and even helping prevent overdose deaths. Unfortunately, prejudices against harm-reduction continue to impede the reach of SSPs.